← Back to headlines
Erasca Stock Falls Following Early-Stage Cancer Therapy Trial Data
Erasca, a rival to Revolution Medicines, experienced a decline in its stock value after releasing early-stage trial data for its cancer therapy.
28 Apr, 11:27 — 28 Apr, 11:27
Sources
Showing 1 of 1 sources
